Shots:

• GSK has stopped the enrollment in its P-II INDUCE-3 trial- including discontinuing treatment with feladilimab- following the recommendation by IDMC
• The P-II INDUCE-3 study involves assessing feladilimab + Merck’s pembrolizumab vs PBO+ pembrolizumab in patients with PD-L1+ recurrent LA/m-HNSCC. Additionally- GSK has also stopped the P-II INDUCE-4 study that evaluates feladilimab vs PBO in combination with pembrolizumab and CT
• Feladilimab is an inducible T cell co-stimulatory agonist. Additionally- the company noted that the totality of the data will be evaluated to assess the impact on the overall clinical development program for the therapy

  Ref: GSK | Image: GSK